CIPLA is currently developing the following drugs: Insulin Glargine, Insulin Lispro-Aabc, Albuterol Sulfate Inhalation Aerosol (90 Mcg Per Actuation), Ventolin Hfa 90Mcg/Actuation Inhalation Aerosol_#1, Ventolin Hfa, 90 Mcg/Inh Inhalation Aerosol_#2, Budesonide 80 Μg And Formoterol Fumarate Dihydrate 4.5 Μg, Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol. These drug candidates are in various stages of clinical development as the company works toward FDA approval.